{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:51:37Z","timestamp":1793742697606,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fam-trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that targets human epidermal growth factor receptor 2 (HER2) and delivers a topoisomerase inhibitor payload. T-DXd has been effectively used to treat metastatic breast cancer but causes pneumonitis in 10\u201315% of cases. Risk factors associated with T-DXd pneumonitis are not well described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research question<\/jats:title>\n                    <jats:p>What are the major clinical risk factors for T-DXd pneumonitis?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of women with metastatic breast cancer at our institution treated with T-DXd as standard of care between 2020 and 2024. We collected clinical data, including demographics, relevant review of symptoms, molecular subtypes, prior treatments, and pulmonary comorbidities, from the electronic health record. A thoracic radiologist reviewed pre-treatment scans for the presence of interstitial lung abnormalities (ILAs). Radiation exposure variables were obtained from an institutional database. Pulmonologists reviewed all cases for the development of pneumonitis. We used univariable and multivariable Cox proportional hazard models to measure the association of clinical variables with the development of pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pneumonitis was observed in 19\/203 patients (9.4%). In univariable analyses, pre-treatment shortness of breath (hazard ratio [HR] 3.9, 95% confidence interval [CI] 1.3\u201311.7), greater number of prior treatments (HR 1.2 per line, 95% CI 1.0-1.4), triple-negative breast cancer (HR 4.9, 95% CI 1.8\u201313.0), low HER-2 status (4.00 (95% CI: 1.43\u201311.11) and pre-treatment ILAs (HR 17, 95% CI 6.5\u201346) were associated with pneumonitis. In multivariable models, pre-treatment ILAs (HR 10.56, 95% CI 3.8-29.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and HER2 (HR 0.30, 95% CI 0.09\u20130.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042) were the strongest predictors of pneumonitis, with a marginal association observed for V20 (HR 1.04, 95% CI 0.99\u20131.09,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.081).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Pre-treatment ILAs and HER2-low breast cancer are major risk factors for T-DXd pneumonitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-025-02151-1","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:30:59Z","timestamp":1762338659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Maria","family":"Azhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma Alicia Vazquez","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Bernal","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Lizarraga","family":"Madrigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Chavez","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Ignacio Rodriguez","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pasyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie R.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Mouabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi K.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia A.","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Bashoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"6","key":"2151_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s1470-2045(19)30097-x","volume":"20","author":"K Tamura","year":"2019","unstructured":"Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab Deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816\u201326. https:\/\/doi.org\/10.1016\/s1470-2045(19)30097-x.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2151_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3816\/cbc.2004.n.011","volume":"5","author":"AM Owens","year":"2004","unstructured":"Owens AM, Horten CB, Silva DMM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63\u20139. https:\/\/doi.org\/10.3816\/cbc.2004.n.011.","journal-title":"Clin Breast Cancer"},{"key":"2151_CR3","first-page":"149","volume":"48","author":"G Carpenter","year":"1978","unstructured":"Carpenter G, Cohen S. Human epidermal growth factor: binding of the polypeptide to human fibroblasts and stimulation of cell proliferation. Natl Cancer Inst Monogr. 1978;48:149\u201356. (In eng).","journal-title":"Natl Cancer Inst Monogr"},{"issue":"11","key":"2151_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejm200103153441101","volume":"344","author":"JD Slamon","year":"2001","unstructured":"Slamon JD, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392. https:\/\/doi.org\/10.1056\/nejm200103153441101.","journal-title":"N Engl J Med"},{"issue":"3","key":"2151_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/jco.2002.20.3.719","volume":"20","author":"LC Vogel","year":"2002","unstructured":"Vogel LC, Cobleigh AM, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in First-Line treatment of <\u2009i\u2009>\u2009HER2-Overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719\u201326. https:\/\/doi.org\/10.1200\/jco.2002.20.3.719.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2151_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/nejmoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Positive breast cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/nejmoa1914510.","journal-title":"N Engl J Med"},{"issue":"22","key":"2151_CR7","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/nejmoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322. https:\/\/doi.org\/10.1056\/nejmoa2407086.","journal-title":"N Engl J Med"},{"issue":"1","key":"2151_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/nejmoa2203690.","journal-title":"N Engl J Med"},{"issue":"2","key":"2151_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000077434","volume":"66","author":"K Yamada","year":"2004","unstructured":"Yamada K, Ikehara M, Tanaka G, Nomura I, Oshita F, Noda K. Dose escalation study of Paclitaxel in combination with Fixed-Dose Irinotecan in patients with advanced Non-Small cell lung cancer (JCOG 9807). Oncology. 2004;66(2):94\u2013100. https:\/\/doi.org\/10.1159\/000077434.","journal-title":"Oncology"},{"issue":"12","key":"2151_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/nejmoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354. https:\/\/doi.org\/10.1056\/nejmoa2115022.","journal-title":"N Engl J Med"},{"issue":"6","key":"2151_CR11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/s1470-2045(19)30088-9","volume":"20","author":"K Shitara","year":"2019","unstructured":"Shitara K, Iwata H, Takahashi S, et al. Trastuzumab Deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(19)30088-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2151_CR12","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab Deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open"},{"issue":"10","key":"2151_CR13","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/s2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang HW, Mueller HS, Denaxas S, Lai GA. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674\u201389. https:\/\/doi.org\/10.1016\/s2666-7568(22)00186-6.","journal-title":"Lancet Healthy Longev"},{"issue":"11","key":"2151_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1164\/rccm.201108-1420pp","volume":"185","author":"JT Doyle","year":"2012","unstructured":"Doyle JT, Hunninghake MG, Rosas OI. Subclinical interstitial lung disease. Am J Respir Crit Care Med. 2012;185(11):1147\u201353. https:\/\/doi.org\/10.1164\/rccm.201108-1420pp.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2151_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/mcp.0000000000000975","volume":"29","author":"M Azhar","year":"2023","unstructured":"Azhar M, Abrencillo R, Gandhi S, Altan M, Sheshadri A. Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease. Curr Opin Pulm Med. 2023;29(4):248\u201355. https:\/\/doi.org\/10.1097\/mcp.0000000000000975.","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s2213-2600(20)30168-5","volume":"8","author":"H Hatabu","year":"2020","unstructured":"Hatabu H, Hunninghake MG, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner society. Lancet Respiratory Med. 2020;8(7):726\u201337. https:\/\/doi.org\/10.1016\/s2213-2600(20)30168-5.","journal-title":"Lancet Respiratory Med"},{"key":"2151_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services. National Institutes of Health. November 27. 2017 (https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf)."},{"issue":"20","key":"2151_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"CA Wolff","year":"2018","unstructured":"Wolff CA, Hammond HEM, Allison HK, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2151_CR19","doi-asserted-by":"publisher","first-page":"00632","DOI":"10.1183\/23120541.00632-2022","volume":"9","author":"H Balata","year":"2023","unstructured":"Balata H, Punjabi A, Chaudhuri N, et al. The detection, assessment and clinical evolution of interstitial lung abnormalities identified through lung cancer screening. ERJ Open Res. 2023;9(3):00632\u20132022. https:\/\/doi.org\/10.1183\/23120541.00632-2022.","journal-title":"ERJ Open Res"},{"issue":"10","key":"2151_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201312-2221pp","volume":"189","author":"M Selman","year":"2014","unstructured":"Selman M, Pardo A. Revealing the pathogenic and Aging-related mechanisms of the enigmatic idiopathic pulmonary Fibrosis. An integral model. Am J Respir Crit Care Med. 2014;189(10):1161\u201372. https:\/\/doi.org\/10.1164\/rccm.201312-2221pp.","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"2151_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"AM Seibold","year":"2011","unstructured":"Seibold AM, Wise LA, Speer CM, et al. A Common\u2009<\u2009i\u2009>\u2009MUC5B\u2009Promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1013660.","journal-title":"N Engl J Med"},{"issue":"7","key":"2151_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1164\/rccm.200804-550oc","volume":"178","author":"TJ Cronkhite","year":"2008","unstructured":"Cronkhite TJ, Xing C, Raghu G, et al. Telomere shortening in Familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(7):729\u201337. https:\/\/doi.org\/10.1164\/rccm.200804-550oc.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2151_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.acra.2009.07.016","volume":"17","author":"RG Washko","year":"2010","unstructured":"Washko RG, Lynch AD, Matsuoka S, et al. Identification of early interstitial lung disease in smokers from the COPDGene study. Acad Radiol. 2010;17(1):48\u201353. https:\/\/doi.org\/10.1016\/j.acra.2009.07.016.","journal-title":"Acad Radiol"},{"issue":"11","key":"2151_CR24","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1093\/oncolo\/oyad118","volume":"28","author":"M Altan","year":"2023","unstructured":"Altan M, Soto F, Zhong LL, et al. Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced Non-Small cell lung cancer: A single center experience. Oncologist. 2023;28(11):e1065\u201374. https:\/\/doi.org\/10.1093\/oncolo\/oyad118.","journal-title":"Oncologist"},{"key":"2151_CR25","doi-asserted-by":"publisher","unstructured":"Han S, Budinger SGR, Gottardi JC. Alveolar epithelial regeneration in the aging lung. J Clin Invest. 2023;133(20). https:\/\/doi.org\/10.1172\/jci170504.","DOI":"10.1172\/jci170504"},{"issue":"4","key":"2151_CR26","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/ijms20040948","volume":"20","author":"N Yehya","year":"2019","unstructured":"Yehya N, Song JM, Lawrence GG, Margulies SS. HER2 signaling implicated in regulating alveolar epithelial permeability with Cyclic stretch. Int J Mol Sci. 2019;20(4):948. https:\/\/doi.org\/10.3390\/ijms20040948.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2151_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1165\/rcmb.2014-0437OC","volume":"54","author":"R Mishra","year":"2016","unstructured":"Mishra R, Foster D, Vasu TV, et al. Cigarette smoke induces human epidermal receptor 2\u2013Dependent changes in epithelial permeability. Am J Respir Cell Mol Biol. 2016;54(6):853\u201364. https:\/\/doi.org\/10.1165\/rcmb.2014-0437OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2151_CR28","doi-asserted-by":"publisher","unstructured":"Stancil TI, Michalski EJ, Davis-Hall D, et al. Pulmonary fibrosis distal airway epithelia are dynamically and structurally dysfunctional. Nat Commun. 2021;12(1). https:\/\/doi.org\/10.1038\/s41467-021-24853-8.","DOI":"10.1038\/s41467-021-24853-8"},{"key":"2151_CR29","doi-asserted-by":"publisher","unstructured":"Liu X, Geng Y, Liang J, et al. HER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts. J Exp Med. 2022;219(10). https:\/\/doi.org\/10.1084\/jem.20220126.","DOI":"10.1084\/jem.20220126"},{"issue":"22","key":"2151_CR30","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/cancers16223753","volume":"16","author":"A Desai","year":"2024","unstructured":"Desai A, Subbiah V, Roy-Chowdhuri S, Sheshadri A, Deshmukh S, Peters S. Association of Antibody\u2013Drug conjugate (ADC) target expression and interstitial lung disease (ILD) in Non-Small-Cell lung cancer (NSCLC): association or causation or neither? Cancers. 2024;16(22):3753. https:\/\/doi.org\/10.3390\/cancers16223753.","journal-title":"Cancers"},{"issue":"3","key":"2151_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463\u2013e47910. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.011.","journal-title":"Cancer Cell"},{"issue":"3","key":"2151_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y-Z Jiang","year":"2019","unstructured":"Jiang Y-Z, Ma D, Suo C, et al. Genomic and transcriptomic landscape of Triple-Negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428\u2013e4405. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.001.","journal-title":"Cancer Cell"},{"key":"2151_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06052-0","author":"M Karaayvaz","year":"2018","unstructured":"Karaayvaz M, Cristea S, Gillespie MS, et al. Unravelling subclonal heterogeneity and aggressive disease States in TNBC through single-cell RNA-seq. Nat Commun. 2018; https:\/\/doi.org\/10.1038\/s41467-018-06052-0.","journal-title":"Nat Commun"},{"issue":"26","key":"2151_CR34","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/nejmoa064320","volume":"355","author":"EC Geyer","year":"2006","unstructured":"Geyer EC, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-Positive advanced breast cancer. N Engl J Med. 2006;355(26):2733\u201343. https:\/\/doi.org\/10.1056\/nejmoa064320.","journal-title":"N Engl J Med"},{"issue":"5","key":"2151_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.24.00529","volume":"43","author":"N Turner","year":"2025","unstructured":"Turner N, Saura C, Aftimos P, et al. Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2\u2013Positive advanced or metastatic breast cancer: an Open-Label, Randomized, phase III trial (TULIP). J Clin Oncol. 2025;43(5):513\u201323. https:\/\/doi.org\/10.1200\/JCO.24.00529.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2151_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa1814017","volume":"380","author":"VG Minckwitz","year":"2019","unstructured":"Minckwitz VG, Huang C-S, Mano SM, et al. Trastuzumab emtansine for residual invasive HER2-Positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/nejmoa1814017.","journal-title":"N Engl J Med"},{"issue":"8","key":"2151_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/op.22.00480","volume":"19","author":"SH Rugo","year":"2023","unstructured":"Rugo SH, Crossno LC, Gesthalter BY, et al. Real-World perspectives and practices for Pneumonitis\/Interstitial lung disease associated with trastuzumab Deruxtecan use in human epidermal growth factor receptor 2\u2013Expressing metastatic breast cancer. JCO Oncol Pract. 2023;19(8):539\u201346. https:\/\/doi.org\/10.1200\/op.22.00480.","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"2151_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-015-0003-5","volume":"15","author":"LM Vold","year":"2015","unstructured":"Vold LM, Aaseb\u00f8 U, Wilsgaard T, Melbye H. Low oxygen saturation and mortality in an adult cohort: the Troms\u00f8 study. BMC Pulm Med. 2015;15(1):9. https:\/\/doi.org\/10.1186\/s12890-015-0003-5.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"2151_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"key":"2151_CR40","doi-asserted-by":"publisher","unstructured":"Li TB, Smit FE, Goto Y et al. Trastuzumab Deruxtecan in HER2.-Mutant Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2022;386(3):241\u201351. https:\/\/doi.org\/10.1056\/nejmoa2112431.","DOI":"10.1056\/nejmoa2112431"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02151-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:16:12Z","timestamp":1781612172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02151-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02151-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved bythe MD Anderson Institutional Review Board (2023-0447).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}